Inflammatix: Funding, Investors & Team (Oct 2026)
Inflammatix develops a novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. The company was founded by Timothy Sweeney and Jonathan Romanowsky in California.
Inflammatix has raised $161M across 3 funding rounds on record, the most recent a Series E of $57.0M announced in Sep 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Inflammatix Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Inflammatix Funding Rounds
Inflammatix raised $102M in a Series D announced in Mar 2021.
8 months later, a Grant of $1.7M was announced in Nov 2021.
2.8 years later, a Series E of $57.0M was announced in Sep 2024.
Inflammatix Founders and Leadership Team
Contact details for the Inflammatix team: 1 of 1 has an email address on file.
Start 14-day free trial →Inflammatix Funding Compared to Other Biotechnology Startups
Inflammatix's latest round of $57.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Inflammatix in Biotechnology and Burlingame
Companies Similar to Inflammatix
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Inflammatix Funding FAQs
What does Inflammatix do?
Inflammatix develops a novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. The company was founded by Timothy Sweeney and Jonathan Romanowsky in California.
How much funding has Inflammatix raised?
Inflammatix has raised $161M across 3 rounds on record. The most recent is a Series E of $57.0M announced in Sep 2024.
When did Inflammatix last raise funding?
Inflammatix's most recent funding round on record is a Series E of $57.0M, announced in Sep 2024.
Who is the CEO of Inflammatix?
Tim Sweeney is listed as CEO at Inflammatix.
Where is Inflammatix headquartered?
Inflammatix is based in Burlingame, California, United States.
How many employees does Inflammatix have?
Inflammatix is in the 101-250 employee band.
How does Inflammatix's funding compare to other Biotechnology startups?
Inflammatix's latest round of $57.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Inflammatix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inflammatix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.